Long-Lasting Response to Lorlatinib in Patients with ALK-Driven Relapsed or Refractory Neuroblastoma Monitored with Circulating Tumor DNA Analysis.
Ek T, Ibrahim RR, Vogt H, Georgantzi K, Träger C, Gaarder J, Djos A, Rahmqvist I, Mellström E, Pujol-Calderón F, Vannas C, Hansson L, Fagman H, Treis D, Fransson S, Österlund T, Chuang TP, Verhoeven BM, Ståhlberg A, Palmer RH, Hallberg B, Martinsson T, Kogner P, Dalin M.
Ek T, et al. Among authors: chuang tp.
Cancer Res Commun. 2024 Sep 1;4(9):2553-2564. doi: 10.1158/2767-9764.CRC-24-0338.
Cancer Res Commun. 2024.
PMID: 39177282
Free PMC article.